Dr Kate Hanrott appointed as Director of Clinical Operations and Sciences
REYKJAVIK, ICELAND – 15 February 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of anti-inflammatory and epithelial barrier-enhancing drugs with a primary focus on chronic respiratory diseases, has appointed Dr Kate Hanrott as Director of Clinical Operations and Sciences, with immediate effect. She brings extensive experience to the role, having spent more than 16 years in the pharmaceutical industry.
Kate spent over 10 years at GSK, most recently as Global Clinical Development Director, where she led clinical operations for a late phase respiratory biologic across multiple indications. While at GSK she held leadership roles in both clinical operations and clinical sciences, working on a broad range of indications (predominantly within respiratory), and across all phases of development - from first in human to pivotal registration trials. Before joining GSK, Kate worked at a specialist clinical pharmacology CRO managing Phase 1 and early Phase 2 clinical trials.
She gained her PhD in pharmacology from the University of Bath, in the UK, and was also a member of the board of examiners at the Faculty of Pharmaceutical Medicine, Royal College of Physicians for over 10 years.
Kate will focus on the operational delivery of EpiEndo’s clinical trials, managing the clinical operations team and CROs. She will also play a crucial role in the clinical development strategy for EpiEndo’s portfolio.
EpiEndo’s Chief Medical Officer, Dr Ginny Norris, commented:
"Kate brings a wealth of experience to the EpiEndo team. Her track record in drug development, and proven success in delivering clinical trials in all phases of development will be key in shaping our clinical development strategy and ensuring the success of our clinical programs.” - ENDS -
About EpiEndo Pharmaceuticals (www.epiendo.com)
EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity to reduce disease-causing inflammation.
Epithelial cells are a key part of the barrier that makes up human lung tissue and other organs such as the gut and skin. A breakdown of this barrier is implicated in several chronic inflammatory diseases.
EpiEndo’s new class of orally available macrolide, with reduced AMR effect, known as a ‘BarriolideTM’, shows promise as a first-in-class therapeutic for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, EP395, is the first BarriolideTM to enter into Phase 2 clinical trials, for chronic obstructive pulmonary disease (COPD).
EP395, aims to be the first on-market oral, barrier strengthening and anti-inflammatory macrolide with reduced AMR effect, for the treatment of COPD, which has a significant unmet need. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD projected to cost $4.8 trillion by 2030.